论文部分内容阅读
研究人员首次证实,帕金森病患者的豆状核内释放神经胶质细胞系衍生的神经营养因子(GDNF)可诱导多巴胺能神经纤维的生成,进而改善患者的临床症状。该研究结果支持英国研究人员在帕金森病动物模型中所观察到的结果。在近期出版的《自然医学》杂志上刊登的该病例报告涉及一例62岁的具有5年的以左半身震颤为主的帕金森病史的男性;与其他4例患者一起,该男性接受神经营养因子输注治疗。因其症状主要在左半身,因此选择右侧豆状核输注。神经营养因子输注持续43个月;患者随后在心肌梗死后3个月左右死亡。该项研究的主要负责人、英国布里斯托尔 Frenchay 医院的Seth Love 博士及其同事对此指出,灌注神经营养因子24个月后,该患者在不用其他药物的情况下,运动能力评分提高38%;与此同时,灌注侧豆状核显示多巴摄取明显增加,相比之下,非灌注侧的多巴摄取则有所降低。
The researchers for the first time confirmed that release of glial cell line-derived neurotrophic factor (GDNF) in the nucleus pulposus of Parkinson’s disease induces the production of dopaminergic nerve fibers and thus improves the patient’s clinical symptoms. The findings support the findings of British researchers in an animal model of Parkinson’s disease. The case report published in the recently published Journal of Natural Medicine relates to a 62-year-old man with a 5-year history of a semibased tremor-based Parkinson’s disease. Along with 4 other patients, the man received neurotrophic factor Infusion therapy. Because of its symptoms mainly in the left half body, so choose the right lentiform nucleus infusion. Infusion of neurotrophic factor lasts for 43 months; the patient subsequently dies about 3 months after myocardial infarction. The study’s lead author, Seth Love, Ph.D., of Frenchay Hospital in Bristol, United Kingdom, and colleagues point out that 24 months after perfusion of neurotrophic factor, the patient improved their ability to exercise without additional medication by 38 %; At the same time, perfusion-side lentiform nuclei showed a significant increase in dopamine uptake, compared to a decrease in non-perfusion dopamine uptake.